186 related articles for article (PubMed ID: 37750106)
1. Comprehensive Review of Ustekinumab Utilization in Inflammatory Bowel Diseases: Insights from the ClinicalTrials.gov Registry.
Alorfi NM; Alourfi MM; Bokhari GA; Alkhattabi A; Ibrahim NA; Alsabban AM; Almatrafi MJ; Zakri YA; Almahmoud AJ; Al-Ghamdi KMA; Alsharif SN
Int J Gen Med; 2023; 16():4283-4294. PubMed ID: 37750106
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Biologic Therapies (Ustekinumab and Vedolizumab) in the Treatment of Inflammatory Bowel Disease (IBD): A Systematic Review.
Ashraf H; Bodapati A; Hanif A; Okafor DK; Katyal G; Kaur G; Khan S
Cureus; 2023 Nov; 15(11):e48338. PubMed ID: 38060699
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
4. Research progress of Ustekinumab in the treatment of inflammatory bowel disease.
Zhang W; Zhong G; Ren X; Li M
Front Immunol; 2024; 15():1322054. PubMed ID: 38455044
[TBL] [Abstract][Full Text] [Related]
5. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Honap S; Meade S; Ibraheim H; Irving PM; Jones MP; Samaan MA
Dig Dis Sci; 2022 Mar; 67(3):1018-1035. PubMed ID: 33723700
[TBL] [Abstract][Full Text] [Related]
7. The Long-Term Clinical Effectiveness of Ustekinumab in Antitumor Necrosis Factor-Experienced Crohn's Disease Patients.
Altuwaijri M; Hakami L; Alharbi O; Almadi M; Alshankiti S; Aljebreen A; Azzam N
Cureus; 2022 Aug; 14(8):e28536. PubMed ID: 36185868
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease.
Gara SK; Guntipalli P; Marzban S; Taqi M; Aryal V; Khan QUA; Shah SA; Akbariromani H; Salinger D; Diaz-Miret M
Cureus; 2023 Oct; 15(10):e46833. PubMed ID: 37954750
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review.
Fang S; Zhang S; Zhang C; Wang L
Paediatr Drugs; 2023 Sep; 25(5):499-513. PubMed ID: 37528211
[TBL] [Abstract][Full Text] [Related]
10. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
[TBL] [Abstract][Full Text] [Related]
11. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
MacDonald JK; Nguyen TM; Khanna R; Timmer A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD007572. PubMed ID: 27885650
[TBL] [Abstract][Full Text] [Related]
12. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
13. Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases.
Wu J; Smogorzewski J
Dermatol Ther; 2021 May; 34(3):e14883. PubMed ID: 33594811
[TBL] [Abstract][Full Text] [Related]
14. Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up To 5 Years in Crohn's Disease and 2 Years in Ulcerative Colitis.
Abraham BP; Ott E; Busse C; Murphy C; Miller L; Baumgart DC; Scherl E; Gasink C
Crohns Colitis 360; 2022 Jul; 4(3):otac025. PubMed ID: 36777422
[TBL] [Abstract][Full Text] [Related]
15. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
Adedokun OJ; Xu Z; Marano C; O'Brien C; Szapary P; Zhang H; Johanns J; Leong RW; Hisamatsu T; Van Assche G; Danese S; Abreu MT; Sands BE; Sandborn WJ
Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2244-2255.e9. PubMed ID: 31816446
[TBL] [Abstract][Full Text] [Related]
16. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
Barré A; Colombel JF; Ungaro R
Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children's hospital in Japan.
Takeuchi I; Arai K; Kyodo R; Sato T; Tokita K; Hirano Y; Shimizu H
J Gastroenterol Hepatol; 2021 Jan; 36(1):125-130. PubMed ID: 32497325
[TBL] [Abstract][Full Text] [Related]
18. Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study.
Burgevin A; Caron B; Sasson A; Luc A; Netter P; Baumann C; Ananthakrishnan AN; Peyrin-Biroulet L
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498541
[TBL] [Abstract][Full Text] [Related]
19. Fecal transplantation for treatment of inflammatory bowel disease.
Imdad A; Nicholson MR; Tanner-Smith EE; Zackular JP; Gomez-Duarte OG; Beaulieu DB; Acra S
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012774. PubMed ID: 30480772
[TBL] [Abstract][Full Text] [Related]
20. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.
Yzet C; Diouf M; Singh S; Brazier F; Turpin J; Nguyen-Khac E; Meynier J; Fumery M
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):668-679.e8. PubMed ID: 32629124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
